Currently Skimming:
10 Developing and Strengthening the Drug Supply Chain for Drug-Resistant TB
10 Developing and Strengthening the Drug Supply Chain for Drug-Resistant TB
Pages 109-118
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 109... ...
• Data and information that underpin drug supply chains form their own information supply chains capable of tracking the risk of infection, preventing the emergence of DR TB, and improving patient follow-up. a Identified by individual speakers.
|
From page 110... ...
Jacobson Professor of Public Health, Department of Immunology and Infectious Diseases, Harvard School of Public Health. "If we had a new effective drug regimen for MDR TB," he said, "we couldn't get it where it needs to be." Failure to reach patients is the result not just of an inconsistent drug supply but also of missteps in the larger system.
|
From page 111... ...
In addition, regulation is lacking, with the result that many drugs may have a low or below-standard dose of the API, and there is a potential market for fake and substandard drugs. Reliable forecasting requires on-the-ground information, including the number of patients enrolled in every TB program, the number taking drugs, and the required lead times for manufacturing and shipping each drug.
|
From page 112... ...
That experience can be leveraged to find solutions. a This box is based on the presentation by Dan Collins, Global Health Programs and Access Department, Corporate Affairs, Eli Lilly and Company.
|
From page 113... ...
The first step toward improving supply chains, Atun suggested, is to understand them in their entirety, as many discussions have focused on selected components of supply chain management systems. At their core, most supply chain management systems comprise a series of manufacturers, along with a storage facility that is central or belongs to a specific region or district.
|
From page 114... ...
AMFm, established by the Global Fund, was successful in reducing prices of innovative malaria drugs by providing indications of increased demand while cofinancing the purchase of certain volumes, thereby reducing the use of ineffective generic malaria drugs previously preferred by patients as a less costly alternative. The Global Fund also worked to overcome issues of fragmented procurement for antietroviral r drugs by establishing voluntary pooled procurement and instituting a transparent Price and Quality Reporting (PQR)
|
From page 115... ...
These data are accessible to the public, grant recipients, and partner agencies. Price transparency made it possible to reduce prices, Atun said, with 91 percent of transactions falling to or below international reference prices within a few years of implementation of the PQR system, and more consistent prices overall across countries receiving Global Fund financing.
|
From page 116... ...
From a business point of view, the fact that only a few patients can be reached, together with significant drug funding issues and a lack of forecasting ability, makes launching new drugs for MDR TB a daunting 4 This section is based on the presentation by Oskar Slotboom, Head, Vaccine and Infectious Diseases, Xian Janssen Pharmaceutical Ltd., Johnson & Johnson.
|
From page 117... ...
This strategy entails working primarily with national programs and certain private clinics, Slotboom explained, as well as supporting current efforts to educate health care professionals. For this drug, some supply chain issues will be less severe than is the case with many other drugs, Slotboom said.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.